A New Fully Accessible, Year-Round Camp for Children with Disabilities. TORONTO–(BUSINESS WIRE)–Kayla’s Children Centre (KCC), a Thornhill-based non-profit organization dedicated to supporting children with disabilities and medical complexities, today announced the creation of Camp Lionheart, a groundbreaking, year-round camp for children with physical, developmental, behavioural, and medical needs. Located on the former site of Camp … [Read more…]

ACCRA, Ghana–(BUSINESS WIRE)–#Africa–The AIDS Healthcare Foundation (AHF) Global Public Health Institute, in collaboration with The Society for AIDS in Africa (SAA), will host a High-Level Summit on Regional Health Leadership and Sustainable Financing in Africa immediately following the opening ceremony of the International Conference on AIDS and STIs in Africa (ICASA 2025) on Dec. 3 … [Read more…]

– The study sponsored by La Nostra Famiglia highlights key brain processes that mediate the effects of omega-3s on literacy development – Further research into the biological mechanisms explaining the effects of omega-3 LCPUFAs on neurocognitive structures and functions is needed to open new pathways for intervention in learning disorders LUGANO, Switzerland–(BUSINESS WIRE)–#GLAsupplements–SFI Health™ EMEA, … [Read more…]

MCLEAN, Va.–(BUSINESS WIRE)–Crux, the first benefits platform partnering with big pharma and employers of all sizes to expand transparent and affordable access to transformative quality-of-life (QoL) medications, today announced its public launch with $6.5 million in pre-seed funding from Red Cell Partners, a venture studio that builds rapidly scalable, technology-led companies that are bringing revolutionary … [Read more…]

New research study aims to treat PTSD and depression, in collaboration with Stony Brook University and Texas A&M MANHASSET, N.Y.–(BUSINESS WIRE)–Recent reports show that one in seven first responders have probable post-traumatic stress disorder (PTSD) in response to routine duties with prevalence increasing after responding to a crisis. To improve our understanding and the well-being … [Read more…]

Annual Thanksgiving event brings together staff, volunteers, and community partners to provide customized food baskets to patients and families LOS ANGELES–(BUSINESS WIRE)–#Family–Luskin Orthopaedic Institute for Children (LuskinOIC) hosted its 25th Annual Holiday Food Basket Giveaway, bringing together hundreds of staff members, volunteers, and community partners to support local families in celebration of Thanksgiving. The event … [Read more…]

New additions streamline data transfer with lesion details, helping make information more accessible for care teams DENVER–(BUSINESS WIRE)–#AI—Cleerly, a leader in AI-based cardiovascular imaging, will showcase new product updates at RSNA 2025, November 30 – December 4, 2025, at McCormick Place in Chicago, IL. At Booth #8039, Cleerly will demonstrate PowerScribe integration and newly added … [Read more…]

Based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the IMFINZI regimen vs. chemotherapy alone WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved … [Read more…]

COPENHAGEN, Denmark–(BUSINESS WIRE)–Keepit, the leader in SaaS data protection, today announced that it has successfully completed the Trusted Information Security Assessment Exchange (TISAX) audit — achieving excellent results with no major findings. TISAX (Trusted Information Security Assessment Exchange) is a European standard for information security assessments developed by the German Association of the Automotive Industry … [Read more…]

VOYXACT achieved a significant placebo-adjusted treatment effect of 51% (P<0.0001) reduction in proteinuria at 9 months of treatment (-50% VOYXACT vs 2% placebo) in the VISIONARY Phase 3 interim analysis. In the study, the most common adverse reactions (reported in ≥10% of patients treated with VOYXACT and at a higher incidence than placebo) reported in … [Read more…]